MAZE
Maze Therapeutics, Inc.
Key Financials
Operating Income
$-142899000
↓ 348.1%
Net Income
$-131120000
↓ 351.0%
Revenue
$167.5M
N/A
Total Assets
$397.1M
↑ 65.1%
Cash & Equivalents
$189.2M
↓ 3.8%
Shareholders' Equity
$355.0M
↑ 214.1%
EPS (Diluted)
$-3.05
↓ 344.0%
Total Liabilities
$42.2M
↓ 3.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| SCHEDULE 13G | 4/1/2026 | View on SEC |
| 4 | 3/31/2026 | View on SEC |
| 3 | 3/31/2026 | View on SEC |
| 144 | 3/30/2026 | View on SEC |
| 10-K | 3/25/2026 | View on SEC |
| 8-K | 3/25/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MAZE |
| Company Name | Maze Therapeutics, Inc. |
| CIK | 1842295 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6508505070 |